Losartan for Corneal Fibrosis
ConditionCorneal Scarring Fibrosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversidad Autonoma de Nuevo Leon
About this trial
This is a prospective, randomized, double-blinded, controlled clinical trial designed to evaluate the efficacy and safety of topical losartan in improving visual acuity, contrast sensitivity and reducing corneal densitometry, corneal aberrations and corneal scarring severity in adult patients with corneal scars of different etiologies. Participants will be randomly assigned to receive either topical losartan 0.8 mg/mL or placebo eyedrops 6 times per day for six months.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Presence of corneal scar with a duration of at least 1 month
Corneal scars of any etiology
Corneal scars with or without corneal neovascularization
Disqualifiers
Refusal or inability to provide written informed consent
Presence of corneal epithelial defect or friable epithelium
Age under 18 years
Pregnancy
Trial design
Treatments tested in this trial
- Topical losartan
- Placebo Control
Treatment groups
46 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov